Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$2.54 USD
+0.05 (2.01%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $2.50 -0.04 (-1.57%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Eledon Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -40.33 | -87.97 | -34.51 | -22.81 | -16.01 |
Depreciation/Amortization & Depletion | 0.37 | 49.02 | 0.20 | 0.18 | 2.05 |
Net Change from Assets/Liabilities | -4.92 | 2.37 | -0.15 | -0.18 | -1.20 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.34 | 8.15 | 5.55 | 7.60 | 1.31 |
Net Cash From Operating Activities | -39.53 | -28.42 | -28.91 | -15.21 | -13.86 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 45.29 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 11.04 | 0.00 |
Net Cash from Investing Activities | -45.29 | 0.00 | 0.00 | 11.04 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 33.02 | 0.00 | 0.00 | 109.61 | 9.68 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.45 | -0.03 | 0.00 |
Net Cash from Financing Activities | 33.02 | 0.00 | -0.45 | 109.58 | 9.68 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -51.80 | -28.42 | -29.36 | 105.40 | -4.18 |
Cash at Beginning of Period | 56.41 | 84.83 | 114.20 | 8.79 | 12.97 |
Cash at End of Period | 4.61 | 56.41 | 84.83 | 114.20 | 8.79 |
Diluted Net EPS | -1.64 | -6.16 | -2.33 | -15.72 | -24.46 |
Fiscal Year End for Eledon Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -68.54 | -10.30 | -40.33 | -30.70 | -20.35 |
Depreciation/Amortization & Depletion | -0.76 | 0.10 | 0.37 | 0.28 | 0.19 |
Net Change from Assets/Liabilities | 3.43 | 0.27 | -4.92 | -4.23 | -0.98 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 49.36 | 1.19 | 5.34 | 4.26 | 3.00 |
Net Cash From Operating Activities | -16.52 | -8.74 | -39.53 | -30.40 | -18.15 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -10.13 | 9.78 | 45.29 | -55.36 | -30.33 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -10.13 | 9.78 | -45.29 | -55.36 | -30.33 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 48.07 | 0.00 | 33.02 | 33.02 | 33.02 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 48.07 | 0.00 | 33.02 | 33.02 | 33.02 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 21.43 | 1.04 | -51.80 | -52.74 | -15.46 |
Cash at Beginning of Period | 4.61 | 4.61 | 56.41 | 56.41 | 56.41 |
Cash at End of Period | 26.04 | 5.66 | 4.61 | 3.67 | 40.95 |
Diluted Net EPS | -1.06 | -0.34 | -0.14 | -0.35 | -0.40 |